Population-based SEER trend analysis of overall and cancer-specific survival in 5138 patients with gastrointestinal stromal tumor

BMC Cancer

Research Article

Ignazio Tarantino¹  Bruno M. Schmied²  Rene Warschkow³  Thomas Cerny⁴  Ulrich Güller⁵ 

[1] Department of General, Abdominal and Transplant Surgery, University of Heidelberg, 69120, Heidelberg, Germany;Department of Surgery, Kantonsspital St. Gallen, 9007, St. Gallen, Switzerland;Department of Surgery, Kantonsspital St. Gallen, 9007, St. Gallen, Switzerland;Institute of Medical Biometry and Informatics, University of Heidelberg, 69120, Heidelberg, Germany;Division of Medical Oncology & Hematology, Kantonsspital St. Gallen, CH-9007, St. Gallen, Switzerland;Division of Medical Oncology & Hematology, Kantonsspital St. Gallen, CH-9007, St. Gallen, Switzerland;University Clinic for Visceral Surgery and Medicine, University Hospital Berne, 3010, Berne, Switzerland;

关键词: Gastrointestinal stromal tumors (GIST);    Surveillance, Epidemiology and End Results (SEER) database;    Trend analysis;    Gastric GIST;   

DOI  :  10.1186/s12885-015-1554-9

 received in 2014-12-16, accepted in 2015-07-14,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundThe objective of the present population-based analysis was to assess survival patterns in patients with resected and metastatic GIST.MethodsPatients with histologically proven GIST were extracted from the Surveillance, Epidemiology and End Results (SEER) database from 1998 through 2011. Survival was determined applying Kaplan-Meier-estimates and multivariable Cox-regression analyses. The impact of size and mitotic count on survival was assessed with a generalized receiver-operating characteristic-analysis.ResultsOverall, 5138 patients were included. Median age was 62 years (range: 18–101 years), 47.3 % were female, 68.8 % Caucasians. GIST location was in the stomach in 58.7 % and small bowel in 31.2 %. Lymph node and distant metastases were found in 5.1 and 18.0 %, respectively. For non-metastatic GIST, three-year overall survival increased from 68.5 % (95 % CI: 58.8–79.8 %) in 1998 to 88.6 % (95 % CI: 85.3–92.0 %) in 2008, cancer-specific survival from 75.3 % (95 % CI: 66.1–85.9 %) in 1998 to 92.2 % (95 % CI: 89.4–95.1 %) in 2008. For metastatic GIST, three-year overall survival increased from 15.0 % (95 % CI: 5.3–42.6 %) in 1998 to 54.7 % (95 % CI: 44.4–67.3 %) in 2008, cancer-specific survival from 15.0 % (95 % CI: 5.3–42.6 %) in 1998 to 61.9 % (95 % CI: 51.4–74.5 %) in 2008 (all PTrend < 0.05).ConclusionsThis is the first SEER trend analysis assessing outcomes in a large cohort of GIST patients over a 11-year time period. The analysis provides compelling evidence of a statistically significant and clinically relevant increase in overall and cancer-specific survival from 1998 to 2008, both for resected as well as metastatic GIST.

【 授权许可】

CC BY   
© Güller et al. 2015